One of the most extensively studied proteins in BC urinary biopsies is Nuclear Matrix Protein 22 (NMP22) and multiple studies have demonstrated the use of this protein as a diagnostic BC biomarker, achieving 75–100% sensitivity and 75.9–91.8% specificity [169,192,193,194]. This evidence concerns the gene NUMA1 and breast cancer.